CD163L1

Summary

CD163L1 (CD163 molecule like 1, HGNC:30375) is a protein-coding gene on chromosome 12p13.31, encoding Scavenger receptor cysteine-rich type 1 protein M160 (Q9NR16).

This gene encodes a member of the scavenger receptor cysteine-rich (SRCR) superfamily. Members of this family are secreted or membrane-anchored proteins mainly found in cells associated with the immune system. The SRCR family is defined by a 100-110 amino acid SRCR domain, which may mediate protein-protein interaction and ligand binding. The encoded protein contains twelve SRCR domains, a transmembrane region and a cytoplasmic domain. Alternative splicing results in multiple transcript variants encoding different isoforms.

Source: NCBI Gene 283316 — RefSeq curated summary.

At a glance

• Gene–disease (curated): schizophrenia (No Known Disease Relationship, GenCC)
• GWAS associations: 2
• Clinical variants (ClinVar): 214 total
• MANE Select transcript: NM_174941

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30375
Approved symbol	CD163L1
Name	CD163 molecule like 1
Location	12p13.31
Locus type	gene with protein product
Status	Approved
Aliases	M160, CD163B, SCARI2, WC1
Ensembl gene	ENSG00000177675
Ensembl biotype	protein_coding
OMIM	606079
Entrez	283316

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 8 protein_coding, 3 retained_intron, 1 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000313599, ENST00000416109, ENST00000539726, ENST00000542055, ENST00000543276, ENST00000543841, ENST00000544331, ENST00000545597, ENST00000545926, ENST00000546182, ENST00000878198, ENST00000878199, ENST00000948251

RefSeq mRNA: 2 — MANE Select: NM_174941 NM_001297650, NM_174941

CCDS: CCDS73434, CCDS8577

Canonical transcript exons

ENST00000313599 — 20 exons

Exon	Start	End
ENSE00001232255	7368087	7368197
ENSE00001232261	7368933	7368965
ENSE00001232266	7369357	7369665
ENSE00001232275	7373320	7373640
ENSE00001232281	7374442	7374756
ENSE00001232287	7374831	7374923
ENSE00001232293	7375281	7375595
ENSE00001232307	7378978	7379298
ENSE00001232316	7396095	7396415
ENSE00001232323	7398264	7398584
ENSE00001232330	7403535	7403855
ENSE00001232336	7406532	7406852
ENSE00001232344	7432416	7432736
ENSE00002252632	7354960	7355130
ENSE00002263388	7444097	7444153
ENSE00003468071	7367236	7367331
ENSE00003545489	7441154	7441246
ENSE00003582117	7375700	7376014
ENSE00003584626	7433374	7433694
ENSE00003659796	7357380	7357486

Expression profiles

Bgee: expression breadth ubiquitous, 176 present calls, max score 91.82.

FANTOM5 (CAGE): breadth broad, TPM avg 1.9151 / max 183.4709, expressed in 478 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
129255	1.1348	319
129260	0.7803	165

Top tissues by expression

250 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
rectum	UBERON:0001052	91.82	gold quality
spleen	UBERON:0002106	91.48	gold quality
ileal mucosa	UBERON:0000331	90.76	gold quality
mucosa of sigmoid colon	UBERON:0004993	89.13	gold quality
mucosa of transverse colon	UBERON:0004991	88.86	gold quality
colonic epithelium	UBERON:0000397	87.55	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.89	gold quality
colonic mucosa	UBERON:0000317	83.96	gold quality
right coronary artery	UBERON:0001625	80.59	gold quality
stromal cell of endometrium	CL:0002255	80.30	gold quality
small intestine Peyer’s patch	UBERON:0003454	79.48	gold quality
jejunal mucosa	UBERON:0000399	78.74	gold quality
small intestine	UBERON:0002108	78.74	gold quality
gall bladder	UBERON:0002110	78.29	gold quality
vermiform appendix	UBERON:0001154	78.05	gold quality
calcaneal tendon	UBERON:0003701	77.96	gold quality
transverse colon	UBERON:0001157	77.81	gold quality
intestine	UBERON:0000160	76.93	gold quality
omental fat pad	UBERON:0010414	76.89	gold quality
peritoneum	UBERON:0002358	76.80	gold quality
large intestine	UBERON:0000059	76.30	gold quality
lymph node	UBERON:0000029	76.17	gold quality
colon	UBERON:0001155	75.90	gold quality
subcutaneous adipose tissue	UBERON:0002190	75.76	gold quality
adipose tissue of abdominal region	UBERON:0007808	75.75	gold quality
left testis	UBERON:0004533	74.99	gold quality
right testis	UBERON:0004534	74.83	gold quality
duodenum	UBERON:0002114	74.24	gold quality
tonsil	UBERON:0002372	73.91	gold quality
smooth muscle tissue	UBERON:0001135	73.72	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.09
E-CURD-10	no	47.07

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

19 targeting CD163L1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-664B-3P	99.84	71.65	3590
HSA-MIR-205-5P	99.81	70.05	1557
HSA-MIR-377-5P	99.70	65.28	712
HSA-MIR-6086	99.70	65.38	699
HSA-MIR-12123	99.52	71.79	2990
HSA-MIR-664A-3P	99.22	71.08	2696
HSA-MIR-4520-2-3P	99.14	69.28	1009
HSA-MIR-3145-3P	98.85	69.07	2031
HSA-MIR-3689A-5P	98.35	70.12	1049
HSA-MIR-3689B-5P	98.35	70.12	1049
HSA-MIR-3689E	98.35	70.12	1049
HSA-MIR-3689F	98.35	70.08	1052
HSA-MIR-7850-5P	98.12	67.28	1111
HSA-MIR-6881-3P	98.04	68.24	1777
HSA-MIR-6779-3P	97.51	65.82	789
HSA-MIR-6866-5P	96.64	68.06	624

Literature-anchored findings (GeneRIF, showing 1)

• CD163L1(+)CXCL10(+) Macrophages are Enriched Within Colonic Lamina Propria of Diverticulitis Patients. (PMID:34256195)

Cross-species orthologs

15 orthologs

Organism	Symbol	Gene ID
danio_rerio	si:ch211-51a6.2	ENSDARG00000030967
danio_rerio	si:ch211-161n3.4	ENSDARG00000045752
danio_rerio	si:dkey-14d8.20	ENSDARG00000045837
danio_rerio	si:ch73-127m5.1	ENSDARG00000060680
danio_rerio	si:ch211-150o23.3	ENSDARG00000078502
danio_rerio	si:ch211-161n3.3	ENSDARG00000092989
danio_rerio	si:dkey-21h14.12	ENSDARG00000094603
danio_rerio	si:ch211-161n3.5	ENSDARG00000095981
danio_rerio	si:dkey-21h14.3	ENSDARG00000096047
danio_rerio	si:dkey-21h14.8	ENSDARG00000096083
danio_rerio	si:dkey-21h14.9	ENSDARG00000096153
danio_rerio	si:dkey-21h14.11	ENSDARG00000096156
danio_rerio	si:dkey-21h14.14	ENSDARG00000096184
danio_rerio	si:dkey-21h14.10	ENSDARG00000096187
drosophila_melanogaster	Loxl2	FBGN0034660

Paralogs (15): CD6 (ENSG00000013725), CD5L (ENSG00000073754), LGALS3BP (ENSG00000108679), CD5 (ENSG00000110448), LOX (ENSG00000113083), LOXL3 (ENSG00000115318), LOXL1 (ENSG00000129038), LOXL2 (ENSG00000134013), LOXL4 (ENSG00000138131), SSC4D (ENSG00000146700), PRSS12 (ENSG00000164099), CD163 (ENSG00000177575), SSC5D (ENSG00000179954), DMBT1 (ENSG00000187908), SCART1 (ENSG00000214279)

Protein

Protein identifiers

Scavenger receptor cysteine-rich type 1 protein M160 — Q9NR16 (reviewed: Q9NR16)

Alternative names: CD163 antigen-like 1

All UniProt accessions (5): Q9NR16, F5H7R7, H0YFE6, H0YFR4, H0YGF0

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Cell membrane Cell membrane Secreted.

Tissue specificity. Isoform 1 is highly expressed in the spleen, lymph nodes, thymus, and fetal liver and weakly expressed in bone marrow and no expression was found in peripheral blood leukocytes. Isoform 1 expression is restricted to the monocyte and macrophage cell lines. Isoform 2 is only expressed in spleen.

Isoforms (4)

UniProt ID	Names	Canonical?
Q9NR16-1	1, M160-alpha	yes
Q9NR16-2	2, M160-beta
Q9NR16-3	3
Q9NR16-4	4

RefSeq proteins (2): NP_001284579, NP_777601* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001190	SRCR	Domain
IPR036772	SRCR-like_dom_sf	Homologous_superfamily

Pfam: PF00530

UniProt features (97 total): disulfide bond 35, glycosylation site 17, domain 12, strand 8, sequence variant 5, sequence conflict 5, splice variant 4, helix 3, topological domain 2, signal peptide 1, chain 1, region of interest 1, compositionally biased region 1, transmembrane region 1, turn 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
6K0O	X-RAY DIFFRACTION	1.99

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NR16-F1	73.07	0.13

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (35): 73–137, 86–147, 117–127, 180–244, 193–254, 224–234, 287–351, 300–361, 331–341, 394–458, 407–468, 438–448, 501–565, 514–575, 545–555, 608–672, 621–682, 652–662, 715–779, 728–789 …

Glycosylation sites (17): 42, 78, 120, 161, 334, 377, 441, 548, 637, 972, 1013, 1084, 1104, 1161, 1171, 1318, 1354

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 57 (showing top): GOCC_CELL_SURFACE, GOBP_VESICLE_MEDIATED_TRANSPORT, GOCC_SIDE_OF_MEMBRANE, GOMF_SCAVENGER_RECEPTOR_ACTIVITY, GOMF_CARGO_RECEPTOR_ACTIVITY, DODD_NASOPHARYNGEAL_CARCINOMA_DN, HOELZEL_NF1_TARGETS_UP, GOCC_EXTERNAL_SIDE_OF_PLASMA_MEMBRANE, BOSCO_TH1_CYTOTOXIC_MODULE, HMGA1_TARGET_GENES, MAFG_TARGET_GENES, MIR5696, MIR12123, MIR664A_3P, MIR4520_2_3P

GO Biological Process (0):

GO Molecular Function (0):

GO Cellular Component (5): extracellular region (GO:0005576), cytoplasm (GO:0005737), external side of plasma membrane (GO:0009897), plasma membrane (GO:0005886), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
intracellular anatomical structure	1
plasma membrane	1
cell surface	1
side of membrane	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

702 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CD163L1	MRC2	Q9UBG0	481
CD163L1	C17orf75	Q9HAS0	431
CD163L1	TESPA1	A2RU30	429
CD163L1	TMEM200B	Q69YZ2	406
CD163L1	IL10RA	Q13651	394
CD163L1	CD68	P34810	389
CD163L1	FREM1	Q5H8C1	368
CD163L1	TRAT1	Q6PIZ9	366
CD163L1	A0A2R8Y6X2	A0A2R8Y6X2	336
CD163L1	ITPRID1	Q6ZRS4	307
CD163L1	CROCC2	H7BZ55	293
CD163L1	OR4C15	Q8NGM1	270
CD163L1	CLEC5A	Q9NY25	270
CD163L1	IL10	P22301	260
CD163L1	MRC1	P22897	260

IntAct

0 interactions, top by confidence:

BioGRID (1): CD163L1 (Cross-Linking-MS (XL-MS))

ESM2 similar proteins: A0A182C2Z2, A1L1V4, A6H737, B4F6N6, B5DF27, B8A4W9, E1C3U7, F1QQC3, F1RD85, F7J220, G3V801, O08762, O18733, O43866, O70244, P14780, P16264, P33434, P33436, P41245, P41246, P50282, P52176, P56730, P58022, P58215, P85521, P98072, P98073, Q08B63, Q2VL90, Q2VLG4, Q2VLG6, Q2VLH6, Q5G265, Q5G266, Q5G267, Q5G268, Q5G269, Q5G270

Diamond homologs: A1L0T3, A1L1V4, A1L4H1, A5PJQ2, A6H737, A7E3W2, B4F6N6, B5DF27, B8A4W9, E1C3U7, F1QQC3, F1RD85, F7J220, G3V801, M9NDE3, O08762, O43866, O70513, P21757, P21758, P30203, P30204, P30205, P56730, P58022, P58215, P70117, P85521, Q05585, Q07797, Q08380, Q08B63, Q14DK5, Q24JV9, Q2VL90, Q2VLG4, Q2VLG6, Q2VLH6, Q4A3R3, Q4G0T1

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

214 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	164
Likely benign	30
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

3311 predictions. Top by Δscore:

Variant	Effect	Δscore
12:7357376:TTACC:T	donor_loss	1.0000
12:7357378:A:AC	donor_gain	1.0000
12:7357378:AC:A	donor_gain	1.0000
12:7357378:ACCTG:A	donor_loss	1.0000
12:7357379:C:CG	donor_gain	1.0000
12:7357379:CC:C	donor_gain	1.0000
12:7357379:CCT:C	donor_gain	1.0000
12:7357379:CCTG:C	donor_gain	1.0000
12:7357379:CCTGG:C	donor_gain	1.0000
12:7357482:GTCAT:G	acceptor_gain	1.0000
12:7357483:TCAT:T	acceptor_gain	1.0000
12:7357484:CAT:C	acceptor_gain	1.0000
12:7357484:CATC:C	acceptor_gain	1.0000
12:7357485:AT:A	acceptor_gain	1.0000
12:7357486:TC:T	acceptor_loss	1.0000
12:7357487:C:CC	acceptor_gain	1.0000
12:7357487:CTGAA:C	acceptor_loss	1.0000
12:7373315:CCCA:C	donor_loss	1.0000
12:7373317:CACCT:C	donor_loss	1.0000
12:7373638:ATT:A	acceptor_gain	1.0000
12:7373639:TT:T	acceptor_gain	1.0000
12:7373641:C:CC	acceptor_gain	1.0000
12:7374758:T:C	acceptor_gain	1.0000
12:7375275:TCTTA:T	donor_loss	1.0000
12:7375276:CTTA:C	donor_loss	1.0000
12:7375277:TTA:T	donor_loss	1.0000
12:7375278:TA:T	donor_loss	1.0000
12:7375279:ACCTG:A	donor_loss	1.0000
12:7375280:C:CT	donor_loss	1.0000
12:7375429:T:TA	donor_gain	1.0000

AlphaMissense

9540 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:7369571:C:A	W1275C	0.999
12:7369571:C:G	W1275C	0.999
12:7406746:C:A	W291C	0.999
12:7406746:C:G	W291C	0.999
12:7398478:C:A	W505C	0.998
12:7398478:C:G	W505C	0.998
12:7398502:C:A	W497C	0.998
12:7398502:C:G	W497C	0.998
12:7374656:C:A	W1065C	0.997
12:7374656:C:G	W1065C	0.997
12:7396309:C:A	W612C	0.997
12:7396309:C:G	W612C	0.997
12:7403749:C:A	W398C	0.997
12:7403749:C:G	W398C	0.997
12:7396333:C:A	W604C	0.996
12:7396333:C:G	W604C	0.996
12:7398313:C:A	W560C	0.996
12:7398313:C:G	W560C	0.996
12:7398359:C:G	C545S	0.996
12:7398360:A:T	C545S	0.996
12:7398376:C:A	W539C	0.996
12:7398376:C:G	W539C	0.996
12:7406770:C:A	W283C	0.996
12:7406770:C:G	W283C	0.996
12:7398329:C:G	C555S	0.995
12:7398330:A:T	C555S	0.995
12:7406748:A:G	W291R	0.995
12:7406748:A:T	W291R	0.995
12:7396190:C:G	C652S	0.994
12:7396191:A:T	C652S	0.994

dbSNP variants (sampled 300 via entrez): RS1000024526 (12:7383090 C>T), RS1000025490 (12:7428315 A>G), RS1000025764 (12:7358403 T>C), RS1000034712 (12:7340724 G>A,C), RS1000089357 (12:7366240 CGGAAAGGGTAGG>C), RS1000110998 (12:7437669 C>T), RS1000122333 (12:7344255 T>C), RS1000124814 (12:7375645 G>A), RS1000174439 (12:7410257 T>G), RS1000178422 (12:7409408 G>A,C,T), RS1000179085 (12:7362128 G>T), RS1000201218 (12:7403507 G>A), RS1000274920 (12:7403972 G>C), RS1000281277 (12:7387952 T>C), RS1000353294 (12:7382770 C>T)

Disease associations

OMIM: gene MIM:606079 | disease phenotypes: MIM:615122

GenCC curated gene-disease

Disease	Classification	Inheritance
schizophrenia	No Known Disease Relationship	Unknown

Mondo (2): lymphoproliferative syndrome 2 (MONDO:0014054), schizophrenia (MONDO:0005090)

Orphanet (1): Combined immunodeficiency due to CD27 deficiency (Orphanet:238505)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST006013_9	Lactate dehydrogenase levels	0.000000e+00
GCST007354_11	Intracranial aneurysm	6.000000e-23

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004808	L lactate dehydrogenase measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

27 total (human), top 27 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases methylation, increases expression	3
butyraldehyde	increases expression, increases methylation	2
Cyclosporine	decreases expression, increases expression	2
dicrotophos	decreases expression	1
propionaldehyde	increases methylation	1
nonanal	increases methylation	1
n-hexanal	increases methylation	1
beta-lapachone	increases expression	1
sodium arsenite	increases expression	1
caprylic aldehyde	increases methylation	1
pentanal	increases methylation	1
heptanal	increases methylation	1
abrine	increases expression	1
jinfukang	affects cotreatment, decreases expression	1
Temozolomide	decreases expression	1
Vorinostat	increases expression	1
Arbutin	decreases expression	1
Arsenic	increases expression	1
Cisplatin	affects cotreatment, decreases expression	1
Methotrexate	decreases expression	1
Silicon Dioxide	increases expression	1
Smoke	increases expression	1
Tobacco Smoke Pollution	increases expression	1
Tretinoin	decreases expression	1
Valproic Acid	decreases methylation	1
Aflatoxin B1	decreases methylation	1
Antirheumatic Agents	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00000374	PHASE4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	PHASE4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	PHASE4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	PHASE4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	PHASE4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	PHASE4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	PHASE4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	PHASE4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	PHASE4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	PHASE4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	PHASE4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	PHASE4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	PHASE4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	PHASE4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	PHASE4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	PHASE4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	PHASE4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	PHASE4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	PHASE4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	PHASE4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	PHASE4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	PHASE4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	PHASE4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	PHASE4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169091	PHASE4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00176423	PHASE4	COMPLETED	Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176436	PHASE4	COMPLETED	Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
NCT00177008	PHASE4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety